The options will support the manufacturing and supply of freeze-dried JYNNEOS, including manufacturing of additional bulk vaccine necessary for fulfilling the contract, as well as supplemental payments, triggered by the demonstration of an extended shelf-life.

These options secure the remaining doses under the original order for 11.5 million doses, and the freeze-dried doses will be manufactured and delivered during 2027. The order for bulk vaccine, which represents the majority of the contract value, is to replace the bulk consumed for liquid-frozen doses supplied to BARDA during the monkeypox outbreak in 2022/23. The vaccine bulk will be invoiced during 2026, and combined with other recent, minor orders, Bavarian Nordic has now secured contracts in the Public Preparedness business in 2026 of approximately DKK 2,000 million, an increase of approximately DKK 600 million compared to the level previously announced. Following this, the Company raises its expectations for the Public Preparedness business in 2026 to revenue of DKK 2,300 – 2,500 million, leading to an upgrade of the overall guidance for 2026. Total revenue of DKK 5,500 – 5,700 million is now expected and the EBITDA margin is expected to reach approximately 28%. See also table below.

“The latest order is a significant milestone in our long standing private-public partnership with the U.S. Government. Almost 10 years ago we started a program together with BARDA to develop a new formulation that would improve the storage and transportation logistics for this vaccine, further improving the preparedness and protection of U.S. citizens. This has seen a freeze-dried smallpox vaccine formulation developed, approved, and next year we will deliver the remaining doses for the 11.5 million order, demonstrating what a strong private-public partnership can achieve in terms of protecting lives from emerging diseases and biological threats,” says Paul Chaplin, President & CEO of Bavarian Nordic.